CMKLR1在乳腺癌中的表达及临床意义

Expression and Clinical Significance of CMKLR1 in Breast Cancer

摘要: 目的：分析CMKLR1在乳腺癌组织的表达情况，探索其在乳腺癌不同分子分型之间的表达差异，及CMKLR1的表达与临床病理特征之间的关联性，为乳腺癌的发生发展、预后及诊疗提供新的思路。方法：利用不同数据库分析趋化因子样受体1 (Chemerin Chemokine-Like Receptor 1, CMKLR1)在乳腺癌中的表达情况。收集2022~2024年扬州大学附属医院确诊的80例乳腺癌及20例正常乳腺组织标本，乳腺癌不同分子分型各20例。运用免疫组织化学染色检测CMKLR1蛋白表达水平，并分析乳腺癌与正常组织间，不同分子分型乳腺癌之间的表达差异及CMKLR1蛋白表达与患者临床病理学特征之间的相关性。结果：scCancerExplorer数据库分析显示，CMKLR1在乳腺癌组织中的表达明显低于正常乳腺组织；Kaplan-Meier Plotter数据库生存预测显示，CMKLR1低表达的乳腺癌患者总生存期明显缩短；UALCAN数据库分析显示，CMKLR1与乳腺癌TNM分期密切相关。免疫组化结果显示：CMKLR1主要以细胞核着色为主，癌组织中的表达明显低于正常组织，差异具有统计学意义(P < 0.001)，而不同分子分型中，在管腔A型与基底样型间存在明显表达差异(基底样型表达更低，P < 0.01)，其他分型之间并无明显表达差异。乳腺癌不同的临床病理特征中，CMKLR1低表达与肿瘤病理分级高(3级)和瘤体较大(>2 cm)有相关性(P < 0.01)，与年龄、TNM分期及淋巴结转移情况无明显关联。结论：CMKLR1在乳腺癌中的表达下调，CMKLR1表达水平与乳腺癌分子分型、病理分级、肿瘤大小相关。CMKLR1对乳腺癌的诊断和预后具有一定辅助诊断价值。

Abstract: Objective: To analyze the expression of CMKLR1 in breast cancer tissues, explore the expression differences among different molecular subtypes of breast cancer, and the correlation between the expression of CMKLR1 and clinicopathological characteristics, so as to provide new ideas for the occurrence, development, prognosis, diagnosis and treatment of breast cancer. Method: The expression of Chemerin Chemokine-Like Receptor 1 (CMKLR1) in breast cancer was analyzed using different databases. Eighty cases of breast cancer and 20 cases of normal breast tissue specimens diagnosed in the Affiliated Hospital of Yangzhou University from 2022 to 2024 were collected, with 20 cases of different molecular classifications of breast cancer each. The expression level of CMKLR1 protein was detected by immunohistochemical staining, and the expression differences between breast cancer and normal tissues, among different molecular subtypes of breast cancer, and the correlation between the expression of CMKLR1 protein and the clinicopathological characteristics of patients were analyzed. Result: The analysis of the scCancerExplorer database showed that the expression of CMKLR1 in breast cancer tissues was significantly lower than that in normal breast tissues. Survival prediction in the Kaplan-Meier Plotter database showed that the overall survival period of breast cancer patients with low expression of CMKLR1 was significantly shortened. Analysis of the UALCAN database shows that CMKLR1 is closely related to the TNM stage of breast cancer. The immunohistochemical results show: CMKLR1 is mainly characterized by nuclear staining. The expression rate in cancer tissues is significantly lower than that in normal tissues, and the difference is statistically significant (P < 0.001). Among different molecular subtypes, there is a significant expression difference between luminal type A and basal-like type (the expression in basal-like type is even lower, P < 0.01), while there is no significant expression difference among other subtypes. Among the different clinicopathological characteristics of breast cancer, the low expression of CMKLR1 was correlated with a high tumor pathological grade (grade 3) and a larger tumor size (>2 cm) (P < 0.01), but had no significant association with age, TNM stage and lymph node metastasis. Conclusion: The expression of CMKLR1 is downregulated in breast cancer, and the expression level of CMKLR1 is related to the molecular typing, pathological grade and tumor size of breast cancer. CMKLR1 has certain auxiliary diagnostic value for the diagnosis and prognosis of breast cancer.